Archived Press Releases

Go to Releases for:

2009

2008

2007

2009

Results of Meeting	Nov 18, 2009
CEO Presentation to Shareholders	Nov 18, 2009
Chairman's Address to AGM	Nov 18, 2009
Appendix 4C Quarterly Cash Flow Report	Oct 30, 2009
Options Update	Oct 23, 2009
Additional Information for AGM	Oct 23, 2009
Annual Report to shareholders	Oct 16, 2009
Notice of Annual General Meeting/Proxy Form	Oct 16, 2009
Movements in Benitec Options	Oct 15, 2009
Benitec secures Rights to T cell HIV Therapeutic	Oct 6, 2009
Collaboration on RNAi Therapeutic for Lung Cancer	Oct 1, 2009
Benitec Biomics Technologies China Update	Sep 7, 2009
Benitec Fully Owned Patent Granted in US	Aug 31, 2009
Appendix 4E and Full Year Annual Report	Aug 28, 2009
Benitec appoints new Chief Scientific Officer	Aug 3, 2009
Final Issue of Shortfall Shares and Options	Jul 31, 2009
Cleansing Notice	Jul 31, 2009
Appendix 3B Shortfall Allotment	Jul 31, 2009
Appendix 4C Quarterly Cash Flow Report	Jul 30, 2009
Benitec US Re-exam Update	Jul 28, 2009
Benitec MOU with Biomics Biotechnologies China	Jul 14, 2009
Further Issue of Shortfall Shares and Options	Jul 2, 2009
Section 708A Notice	Jul 2, 2009
Appendix 3B Shortfall Allotment	Jul 2, 2009
Expiry of Unlisted Options	Jun 29, 2009
Further Issue of Shortfall Shares and Options	Jun 12, 2009
Section 708A Notice	Jun 12, 2009
Appendix 3B Shortfall Allotment	Jun 12, 2009
Further Issue of Shortfall Shares and Options	May 27, 2009
Section 708A Notice	May 27, 2009
Appendix 3B Shortfall Allotment	May 27, 2009
Benitec US Re-exam Update	May 26, 2009
Issue of Shortfall Shares and Options Update	May 18, 2009
Section 708A Notice	May 18, 2009
Appendix 3B Shortfall Allotment	May 18, 2009
Change in Substantial Holding	May 12, 2009
Appendix 3B Completion of Rights Issue	May 7, 2009
Completion of Rights Issue	May 7, 2009
Benitec and City of Hope Human Trial Update	May 6, 2009
Benitec US Re-exam Update	May 5, 2009
Rights Issue - Notification of Shortfall	May 4, 2009
Closing of Non-Renounceable Rights Issue	Apr 30, 2009
Appendix 4C Quarterly Cash Flow Report	Apr 30, 2009
Final Director's Interest Notice	Apr 24, 2009
Director Resignation	Apr 17, 2009
Appendix 3B Rights Issue Correction	Apr 8, 2009
Company Contact Details	Apr 6, 2009
Letter to Option Holders	Apr 1, 2009
Non Renounceable Rights Issue Appendix 3B	Apr 1, 2009
Non Renounceable Rights Issue Prospectus	Apr 1, 2009
Benitec US Re-exam Update	Mar 26, 2009
Movements in Benitec Shares and Options	Mar 24, 2009
Benitec withdraws from renegotiations with CSIRO	Mar 12, 2009
Half Year Report and Accounts	Feb 27, 2009
Change in Substantial Holding	Feb 10, 2009
City of Hope Human Trial Update	Feb 9, 2009
Benitec confirms Capital Raising	Feb 9, 2009
Appendix 4C - Quarterly Cash Flow Report	Jan 30, 2009
Results of General Meeting	Jan 7, 2009

2008

US Patent Reexam Further Update	Nov 28, 2008
US Patent Reexam Update	Nov 21, 2008
Benitec Announces Prudent Cash Management Strategy	Nov 20, 2008
Results of Meeting	Nov 19, 2008
CEO Presentation to AGM	Nov 19, 2008
Chairman's Address to Shareholders	Nov 19, 2008
Change in Substantial Holding	Nov 11, 2008
Benitec Double-Stranded Patent Granted in Singapore	Nov 6, 2008
Appendix 3B - Share Placement	Nov 6, 2008
Appendix 4C - Quarterly Cash Flow Report	Oct 30, 2008
City of Hope Human Trial Update	Oct 23, 2008
Private Placement Raises $1.97M	Oct 22, 2008
Notice of Annual General Meeting and Proxy Form	Oct 20, 2008
Graham Gene Silencing Patent Granted in New Zealand	Oct 17, 2008
2008 Annual Report	Oct 9, 2008
2008 Full Year Statutory Accounts	Sep 26, 2008
Preliminary Final Report for Year ended 30 June 2008	Aug 29, 2008
Benitec Double-Stranded Patent Granted in New Zealand	Aug 8, 2008
Appendix 4C - Quarterly Cash Flow Report	Jul 22, 2008
Dr Zaia Update on HIV Lymphoma Study at ASGT Conference	Jun 6, 2008
Benitec delays Capital Raising	May 23, 2008
Proposed Underwritten Non-Renounceable Rights Issue	May 16, 2008
Appendix 4C - Quarterly Cash Flow Report	Apr 29, 2008
Benitec secures further rights to HIV Therapeutic	Apr 29, 2008
Benitec wins in US Supreme Court	Apr 22, 2008
US Patent Reexam Update	Apr 21, 2008
Reinstatement to Official Quotation	Apr 21, 2008
Suspension from Official Quotation	Apr 16, 2008
Request for Voluntary Suspension	Apr 16, 2008
Trading Halt	Apr 14, 2008
Request for Trading Halt	Apr 14, 2008
Exercise of Options	Apr 11, 2008
Investor Update	Apr 7, 2008
Dr Rossi presents update on HIV lymphoma study at Keystone meeting	Mar 31, 2008
Expiry of Unlisted Options	Mar 27, 2008
Benitec licensee’s Oncolys deal to commercialise Hep C drug	Mar 13, 2008
Benitec US Reexam Update	Mar 12, 2008
Change of Director's Interest Notice	Mar 7, 2008
Changes to Unlisted Options and Appendix 3B	Mar 6, 2008
Half Year Report and Accounts	Feb 29, 2008
Final Director's Interest Notice	Feb 26, 2008
Board Changes	Feb 26, 2008
Corporate Flyer Jan-08	Feb 5, 2008
Presentation to BioPartnering North America	Feb 5, 2008
Benitec at BioPartnering North America meeting	Feb 5, 2008
Response to ASX Query	Feb 5, 2008
Appendix 4C - Quarterly Cash Flow Report	Jan 30, 2008
Ceasing to be a substantial shareholder	Jan 10, 2008
Update on Nucleonics Request to US Supreme Court	Jan 10, 2008
Response to ASX Query	Jan 8, 2008
Benitec's Licensee confirms Hepatitis C deal with Pfizer	Jan 8, 2008
Trading Halt	Jan 8, 2008
Trading Halt Request	Jan 8, 2008
Nucleonics files Request to US Supreme Court	Jan 4, 2008
Company Response to ASX Price Query	Jan 3, 2008

2007

Change of Director's Interest Notice	Dec 11, 2007
Change of Director's Interest Notice	Dec 6, 2007
Change of Director's Interest Notice	Dec 6, 2007
Change of Director's Interest Notice	Dec 6, 2007
Appendix 3B Issue of Options	Dec 6, 2007
Change of Director's Interest Notice	Dec 5, 2007
Results of Meeting	Nov 28, 2007
Chairman's Address to Shareholders	Nov 28, 2007
Appendix 3B Exercise of Options	Nov 2, 2007
Shareholder acquires Additional Equity Stake	Oct 31, 2007
Appendix 3B Loan Conversion	Oct 31, 2007
2007 Annual Report	Oct 26, 2007
Notice of Annual General Meeting	Oct 26, 2007
Appendix 4C - Quarterly Cash Flow Report	Oct 26, 2007
Benitec AusBiotech Conference Presentation	Oct 23, 2007
Benitec presents at National AusBiotech Conference	Oct 23, 2007
Initial Director's Interest Notice	Oct 16, 2007
Investor Presentation for US Roadshow	Oct 15, 2007
Benitec conducts US roadshow	Oct 15, 2007
Benitec appoints Mel Bridges Non-Executive Director	Oct 12, 2007
Notice of Initial Substantial Holder	Oct 11, 2007
Benitec Investor Presentation Oct-07	Oct 10, 2007
Benitec presents at Intersuisse Asia Pacific LifeScience Forum	Oct 10, 2007
US-based Promega Corp acquires additional equity stake	Oct 8, 2007
Appendix 3B Conversion of Promissory Note	Oct 8, 2007
Benitec at BioPartnering Europe Meeting	Oct 8, 2007
Nucleonics petition denied in US Court	Oct 5, 2007
Full Year Statutory Accounts 2007	Sep 5, 2007
Preliminary Final Report for Year ended 30 June 2007	Aug 31, 2007
Share Registry Change of Location	Aug 30, 2007
Appendix 3B ESOP Options	Aug 30, 2007
Benitec appoints Chief Scientific Officer	Aug 21, 2007
Benitec MOU with CalbaTech, Inc.	Aug 17, 2007
Investor Update	Aug 9, 2007
Initial Director's Interest Notice	Aug 8, 2007
Patent Reexam and Litigation Update	Aug 8, 2007
Commitments Test Entity - Fourth Quarter Report	Jul 31, 2007
Benitec wins in US Court	Jul 23, 2007
CEO of Benitec joins Board	Jul 2, 2007
New Benitec website: better investor communications	Jun 27, 2007
Benitec appoints new Scientific Advisory Board	Jun 20, 2007
Commences HIV Study in Humans in Los Angeles	Jun 13, 2007
Change of Director's Interest Notice x 2	May 14, 2007
Change in substantial holding	May 11, 2007
Benitec bio-partnering at BIO2007	May 7, 2007
Benitec features at prestigious Boston meeting	May 4, 2007
Commitments Test Entity - Third Quarter Report	Apr 30, 2007
London Investor Update	Apr 27, 2007
Files US Patent Response	Apr 26, 2007
European Patent Update	Apr 26, 2007
Investor Update	Apr 16, 2007
Change in substantial holding	Apr 13, 2007
New CFO Appointed	Apr 13, 2007
Change in substantial holding	Apr 13, 2007
Completion of Rights Issue & Top 20 Share & Option holders	Apr 4, 2007
Phase I Study Update	Apr 2, 2007
Becoming a substantial holder	Apr 2, 2007
Becoming a substantial holder	Apr 2, 2007
Shortfall in Rights Issue	Mar 29, 2007
Patent Re-examination Update	Mar 16, 2007
Non-Renounceable Issue	Mar 5, 2007
Becoming a substantial holder	Mar 2, 2007
Half Year Accounts	Mar 1, 2007
Half Yearly Report	Mar 1, 2007
Preliminary Half Year Report for Period Ending 31 December 2006	Feb 28, 2007
Rights Issue Prospectus	Feb 28, 2007
Rights Issue Announcement	Feb 26, 2007
Benitec Options Update	Feb 26, 2007
Results of General Meeting	Feb 21, 2007
Benitec Patent and Litigation Update	Feb 13, 2007
Benitec Patent Re-examination Update	Feb 6, 2007
Trading Halt	Jan 30, 2007
Quarterly Report for Entities admitted on the basis of commitments	Jan 30, 2007
Additional Information for General Meeting	Jan 8, 2007
Sigma-Aldrich licences Pfizer to use Benitec Technology	Jan 5, 2007
Revised Notice of General Meeting	Jan 5, 2007
Benitec Receives $650k Investment Support	Jan 3, 2007
John Rawling Appointed as Co-Company Secretary and Accountant	Jan 3, 2007
Notice of General Meeting	Jan 3, 2007

2006

Change in substantial holding	Dec 28, 2006
Results of AGM	Dec 28, 2006
CEO Presentation	Nov 30, 2006
Chairman's Address to Shareholders	Nov 30, 2006
Additional Information for AGM	Nov 30, 2006
Presentation at AusBiotech National Biotech Conference	Nov 30, 2006
Final Annual Report 2006	Oct 31, 2006
Commentary on Benitec Ltd Share Price	Oct 31, 2006
Additional Information Re ASX Price Query	Oct 30, 2006
Response to ASX Share Price Query	Oct 25, 2006
Commitments Test Entity - First Quarter Report	Oct 23, 2006
Notice of Annual General Meeting	Oct 23, 2006
Reinstatement to Official Quotation	Oct 17, 2006
Full Year Statutory Accounts 2006	Oct 17, 2006
Ceasing to be a Substantial Shareholder	Oct 11, 2006
Benitec Secures New Investment Support	Oct 11, 2006
Benitec Executes New RNAi License Deal with Tacere Therapeutics	Oct 10, 2006
Appendix 3B - New Issue Announcement	Oct 6, 2006
US-Based Promega Corp Acquires Equity Stake in Benitec	Sep 29, 2006
Benitec Update on Audited Accounts	Sep 25, 2006
Benitec Accounts Update	Sep 14, 2006
Benitec Appoints Paul McMahon as CFO & Company Secretary	Sep 14, 2006
Change in substantial holding	Sep 11, 2006
Preliminary Final Report	Aug 28, 2006
Share Purchase Plan	Aug 25, 2006
Benitec Appoints Sue MacLeman as CEO	Aug 22, 2006
Benitec Announces Share Purchase Plan Extension Offer	Aug 8, 2006
Benitec negotiates reduced CSIRO royalties	Aug 8, 2006
Revised Share Purchase Plan Application Form	Aug 8, 2006
Revised Shareholder Share Purchase Plan	Jul 31, 2006
Share Purchase Plan - Pricing Restructure	Jul 26, 2006
Commitments Test Entity - Fourth Quarter Report	Jul 26, 2006
Shareholder Share Purchase Plan	Jul 26, 2006
Letter to Shareholders Regarding Share Purchase Plan	Jun 29, 2006
News Release: Share Purchase Plan	Jun 29, 2006
Final Director's Interest Notice - Michael Catelani	Jun 22, 2006
Final Director's Interest Notice - Sara Cunningham	Jun 22, 2006
Benitec Resumes Manufacturing of HIV/AIDS Therapeutic	Jun 5, 2006
Benitec Shuts Down U.S. Operations and Restructures Board	May 25, 2006
Benitec to Present at the American Society of Gene Therapy 9th Annual Meeting	May 23, 2006
Benitec Provides Context for Nature Paper on RNAi	May 22, 2006
Half Yearly Report Clarification	May 10, 2006
Final Director's Interest Notice - Alexander Cappello	Apr 28, 2006
New Issue Announcement - Appendix 3B	Apr 18, 2006
Commitments Test Entity - Third Quarter Report	Apr 18, 2006
Benitec featured on ABC-TV’S Catalyst	Apr 17, 2006
Benitec Implements Cost Reductions	Apr 11, 2006
Director Resignation - Alex Cappello	Apr 4, 2006
Ceasing to be a substantial holder - Barbary Coast Investments Benitec Featured in BioPharm International Biopartnering Down Under article	Mar 24, 2006
Benitec Announces Appointment of Dr. Mike Dalling to its Board of Directors	Mar 24, 2006
Benitec Announces Appointment of Peter Francis as Chairman of the Board of Directors	Feb 23, 2006
Benitec Announces Appointment of Company Secretary and Change of Registered Address	Feb 23, 2006
Benitec Appoints Two New Directors	Feb 8, 2006
Benitec Delays IND Filing for HIV/AIDS Therapeutic Pending Resolution of Manufacturing Result.	Jan 30, 2006

2005

Benitec Featured in International Herald Tribune article	Dec 31, 2005
Benitec Grants Sigma-Aldrich License to RNAi Patent Portfolio	Oct 23, 2005
Benitec Successfully Resolves Patent Infringement Litigation	Oct 3, 2005
Benitec Patents Upheld in Australia Benitec and Promega Settle Litigation	Aug 23, 2005
Benitec Quarterly Report	Aug 21, 2005
Benitec Granted Exclusive Worldwide License to Calando’s RNAi Delivery Technology for Benitec's Hepatitis C Therapeutic	Jun 30, 2005
Benitec to Present Preclinical Data on its Hepatitis C Virus Program at the American Society for Gene Therapy Meeting	Jun 20, 2005
Benitec Announces Clinical Candidate for the Treatment of Hepatitis C	May 24, 2005
Benitec Appoints Chief Financial Officer	May 9, 2005
Benitec and Alnylam Form Alliance on Fundamental Intellectual Property for	Apr 13, 2005
RNAi Therapeutics	Apr 12, 2005
Benitec Announces Underwritten Rights Issue to Raise Up To $9.7 Million	Apr 6, 2005
Benitec Announces Registered Office Address Change	Mar 30, 2005
Benitec Grants Worldwide ddRNAi License to Genoway	Mar 22, 2005
Benitec Adds Leading Hematology Researcher and FDA Advisor to Scientific Advisory Board	Mar 15, 2005
Appointment of Company Secretary	Mar 1, 2005
Benitec and Combimatrix Enter Cross-Licensing and Collaboration Agreement	Feb 23, 2005
Benitec Announces National Institutes of Health (NIH) Funded AIDS Collaboration	Feb 21, 2005
Benitec Appoints Sara Cunningham to Board of Directors	Feb. 9, 2005
Benitec and The Garvan Institute to Develop Novel Drugs for Diabetes and Obesity using Garvan's "Hotmouse" Technology	Feb. 3, 2005
Benitec Appoints Alexander L. Cappello to Board of Directors	Feb. 3, 2005
Benitec Online Conference	Jan. 31, 2005
Appointment of Chairman and CEO	Jan. 18, 2005

2004

Benitec Announces Litigation Status	Dec 2, 2004
Benitec Grants ddRNAi License to Artemis Pharmaceuticals GmbH, Cologne for Commercial Development of Transgenics	Oct 28, 2004
Benitec Announces Additional Non-Exclusive Worldwide License to Research Reagent Company & the Issue of Its Hong Kong Patent	Oct 20, 2004
Benitec Obtains Exclusive License to Unique RNAi Non-Viral Delivery Technology from Stanford University	Oct 15, 2004
Benitec and City of Hope Announce HIV/AIDS collaboration and Initiation of the World's First RNAi Based HIV Clinical Development Program	Aug 25, 2004
Benitec Settles Infringement Litigation with Genscript & Announces Grant of Second UK Patent	Aug 23, 2004
Benitec Announces Appointment of Capello Capital Corporation as Exclusive Strategic Advisors and Investment Bankers to the Company	Aug 16, 2004
Benitec Settles Infringement Litigation Against Ambion and Grants a Non-Exclusive Worldwide License to Make and Sell ddRNAi Products	Aug 10, 2004
Benitec and Promega Grant Non Exclusive Worldwide License to Merck to use ddRNAi in Exclusive Research Programs	Jul 5, 2004
Benitec Expands Management Team	Jun 18, 2004
Benitec Acquires Avocel and establishes US operations	May 17, 2004
Benitec Appoints Rob Thomas (Citigroup) as Deputy Chairman	May 7, 2004
Eminent Scientists Join Benitec's Scientific Advisory Board	Apr 21, 2004
Appendix 4C - Highlights for Quarter ended 31 March 2004	Mar 26, 2004
Benitec Initiates Patent Infringement Lawsuit to Protect RNAi Gene Silencing Technology	Mar 26, 2004
DNA-Delivered RNAi Products for Research Applications Launched by Promega	Mar 5, 2004
Trading of BLT Shares on the Berlin and Frankfurt Stock Exchanges	Feb 24, 2004
Promega Corporation Sub-licensed Chemicon International	Feb 18, 2004
Corporate Presentation	Jan 15, 2004

2003

Placement Announcement	Dec 9, 2003
Milestone Strategic Agreement Benitec CSIRO & QDPI	Dec 8, 2003
Benitec Achieves Major Breakthrough in Gene Silencing	Oct 22, 2003
Tranzyme: Tranzyme Receives Funding from North Carolina Biotechnology Center Through Small Business Research Award Program	Sep 23, 2003
Dr John Rossi to Chair Benitec's U.S. Scientific Advisory Board	Sep 18, 2003
Garvan Institute extends Diabetes Research Collaboration	Jul 17, 2003
Queensland Government: Queensland Scores Gene Technology Coup	Jun 24, 2003
Benitec Granted First US & UK Patents for DNA-Directed Gene Silencing	Jun 5, 2003
Benitec and Promega Announce Worldwide Exclusive License for RNAi Products \| Promega Fact Sheet	Apr 8, 2003
Benitec and Tranzyme Announce Collaboration Agreement for Gene Silencing Technology	Feb 27, 2003
Benitec Acquires Patent for Fast-Tracking Drug Development	Jan 7, 2003

2002

Benitec and The Garvan Institute Collaborate on Diabetes Benitec First to Show Stable Gene Silencing in Animals	Dec 12, 2002
Queensland Government: Cruise Missile of Gene Technology is Biggest Biotech Breakthrough for Decade	Sep 16, 2002
Australian Biotech's Gene Silencing to Unleash a Global Storm	Jun 23, 2002

Return to Top of Page